Vivimed Labs Ltd (VIVIMEDLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Vivimed Labs Ltd on NSE and BSE, with an AI summary of each filing.
Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome · 15 Oct 2026, 5:55 pm
Vivimed Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Million) ■ Revenue: 120 (-53.2% YoY | -24.9% QoQ) ■ EBITDA: -1,403 (-5593.1% YoY | -1195.0% QoQ) ■ EBITDA Margin (%): -1,169 (-115937 bps YoY | -110125 bps QoQ) ■ PAT: -1,471 (-2527.2% YoY | -788.7% QoQ) ■ EPS (INR): -17.2 (-2509.1% YoY | -787.6% QoQ)
intimation of meeting of committee of creditors
Others (Uncategorized) · 27 Sept 2026, 2:08 am
Vivimed Labs Schedules 8th Committee of Creditors Meeting Under CIRP Vivimed Labs Limited has issued a pre-facto intimation regarding the 8th meeting of its Committee of Creditors (CoC), scheduled for 29th Sep'26 via audio-visual means. The company is currently undergoing a Corporate Insolvency Resolution Process (CIRP) pursuant to an NCLT order dated 15th Apr'26. The meeting is being convened by the Interim Resolution Professional, T Narayana Swamy, under Regulation 19 of the IBBI CIRP Regulations and SEBI LODR requirements.
Seeking time for holding an AGM
Annual General Meeting · 26 Sept 2026, 8:11 pm
Committee of Creditors meeting on 10th September 2026
Others (Uncategorized) · 08 Sept 2026, 10:01 pm
Vivimed Labs Schedules Seventh Committee of Creditors Meeting Vivimed Labs Limited, currently under Corporate Insolvency Resolution Process (CIRP) pursuant to an NCLT order dated 15th Apr'26, announced that the 7th meeting of its Committee of Creditors (CoC) is scheduled for 10th Sep'26. The meeting will be conducted via audio-visual means in compliance with Regulation 19 of the IBBI CIRP Regulations, 2016, and SEBI LODR Regulation 30 guidelines, as confirmed by Interim Resolution Professional T Narayana Swamy.
6th COC meeting on 18th August 2026
Others (Uncategorized) · 17 Aug 2026, 10:10 pm
Vivimed Labs Schedules 6th Committee of Creditors Meeting Amid Insolvency Vivimed Labs, currently under a Corporate Insolvency Resolution Process (CIRP), has scheduled its 6th Committee of Creditors (CoC) meeting for Tue, 18th Aug'26. The meeting will be conducted via audio-visual means. This follows five prior CoC meetings held between May'26 and Jul'26. The CIRP was initiated following an NCLT order dated 15th Apr'26. The outcome of the CoC meeting is critical for the company's resolution plan and future direction.
re-lodgement of transfer requests
Others (Uncategorized) · 22 Jul 2026, 10:27 pm
Vivimed Labs Reports No Physical Share Transfer Re-lodgements in Jun'26 Vivimed Labs submitted a report from its Registrar and Transfer Agent, Aarthi Consultants, dated 06-Jul'26, detailing the status of re-lodged physical share transfer requests for Jun'26. The filing, made in compliance with a SEBI circular, confirms that no requests were received, processed, approved, or rejected during the month. Consequently, there was no activity related to the re-lodgement of physical share transfers for the period.
results for FY 2025-2026
Financial Result · 17 Jul 2026, 11:53 pm
Vivimed Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Million) ■ Revenue: 120 (-53.2% YoY | -24.9% QoQ) ■ EBITDA: -1,403 (-5593.1% YoY | -1184.4% QoQ) ■ EBITDA Margin (%): -1,169 (-115937 bps YoY | -110068 bps QoQ) ■ PAT: -1,460 (-2742.8% YoY | -782.2% QoQ) ■ EPS (INR): -17.7 (-2508.8% YoY | -787.0% QoQ)
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/07/2026 ,inter alia, to consider and approve quarter & year end results (31.3.2026)
Intimation · 17 Jul 2026, 5:30 am
Vivimed Labs Board Meeting Scheduled for Jul'26 to Approve Q4 FY26 Results Vivimed Labs (NSE: VIVIMEDLAB) announced its Board of Directors will meet on 17th Jul'26 in Hyderabad. The key agenda is to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ending 31st Mar'26. This meeting will be a crucial event for the stock, as the full-year earnings and management outlook for FY27 will be disclosed. Any other relevant items may also be discussed.
form G
Others (Uncategorized) · 17 Jun 2026, 7:02 pm
Vivimed Labs Invites Expressions of Interest Under Insolvency Resolution Process Vivimed Labs has issued an invitation for expressions of interest (EOI) as part of its Corporate Insolvency Resolution Process. The EOI covers its pharma dosage manufacturing facilities in Hyderabad, Haridwar, Kashipur, and a non-operational unit in Bidar. The company reported revenue from operations of INR 103.60 Cr for FY25 and INR 136.80 Cr for FY24. The deadline for submitting EOIs is 29-Jun'26, and the final date for submitting resolution plans is 28-Aug'26. The company employs 552 people.
Board meeting Postponed
Others (Uncategorized) · 30 May 2026, 8:47 pm
Vivimed Labs Postpones Board Meeting for FY26 Results Vivimed Labs announced the postponement of its Board Meeting originally scheduled for 30 May'26. The meeting was intended to approve the financial results for the quarter and year ended FY 2025-26. A revised date will be announced in due course. Consequently, the trading window for designated persons will remain closed until 48 hours after the declaration of financial results at the rescheduled meeting. This delay in reporting key financial results could introduce uncertainty for investors regarding the company's performance.
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve audited results for FY 2025-2026
Intimation · 30 May 2026, 5:30 am
Vivimed Labs Board Meeting Scheduled for 28-May-26 Vivimed Labs Limited (BSE: 532660, NSE: VIVIMEDLAB) has scheduled a Board of Directors meeting for Thu, 28-May-26. The agenda includes the consideration and approval of the audited standalone and consolidated financial results for the quarter and financial year ending 31-Mar-26. This meeting is crucial for investors as it will provide key performance data for Q4 FY26 and the full fiscal year, influencing the company's stock outlook.
Form A - Public Announcement
Others (Uncategorized) · 23 Apr 2026, 6:44 pm
Vivimed Labs Enters Corporate Insolvency Resolution Process The National Company Law Tribunal, Bengaluru Bench, has initiated a Corporate Insolvency Resolution Process for Vivimed Labs Limited, effective 15-Apr-26. The NCLT order was received on 17-Apr-26. Mr. T Narayana Swamy has been appointed as the Interim Resolution Professional. Creditors are required to submit their claims with proof by 01-May-26. The estimated closure date for the insolvency resolution process is set for 11-Oct-26. This action follows regulatory protocols under the Insolvency and Bankruptcy Code, 2016.
ADMISSION TO CIRP
Others (Uncategorized) · 17 Apr 2026, 9:33 pm
Vivimed Labs Admitted to Corporate Insolvency Resolution Process (CIRP) The NCLT Bengaluru Bench admitted Vivimed Labs into the Corporate Insolvency Resolution Process (CIRP) via an order dated 15 Apr'26. The petition was filed by operational creditor Blue Cube Germany Assets for a default of ₹2.78 crore. The NCLT established the existence of an operational debt and default, rejecting Vivimed's objections regarding limitation and maintainability. A moratorium under Section 14 of the IBC has been imposed, and Shri T Narayana Swamy has been appointed as the Interim Resolution Professional (IRP).
Initial disclosure- Not Large corporate
Others (Uncategorized) · 06 Apr 2026, 8:41 pm
Vivimed Labs Declares It Is Not a 'Large Corporate Entity' Vivimed Labs Limited (NSE: VIVIMEDLAB) informed exchanges on 06-Apr-26 that it does not qualify as a 'large corporate entity' under the framework defined by SEBI's circular dated 26-Nov-18. This declaration clarifies the company's status regarding specific fundraising and compliance norms applicable to large corporates, confirming it is outside the purview of these particular regulations.
Q3 FY 2026 RESULTS
Financial Result · 14 Mar 2026, 4:08 am
VIVIMED LABS LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Million) ■ Revenue: 160 (-56.2% YoY | -22.4% QoQ) ■ EBITDA: -109 (Profit to Loss YoY | -1044.9% QoQ) ■ EBITDA Margin (%): -68.3 (Profit to Loss YoY | -6368 bps QoQ) ■ PAT: -166 (-177.1% YoY | -126.7% QoQ) ■ EPS (INR): -1.94 (-177.1% YoY | -169.4% QoQ)
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2026 ,inter alia, to consider and approve Notice of Board meeting
Intimation · 13 Mar 2026, 5:30 am
Vivimed Labs Board Meeting on 13th Mar'26 to Approve Q3FY26 Results Vivimed Labs (NSE: VIVIMEDLAB) announced its Board of Directors will meet on Friday, 13th Mar'26, in Hyderabad. The primary agenda is to consider and approve the company's unaudited standalone and consolidated financial results. This review will cover the quarter and nine-month period ending 31st Dec'25. The Board will also address any other relevant items during the meeting.
updates (additional information)
Others (Uncategorized) · 16 Feb 2026, 4:40 pm
Vivimed Labs Obtains High Court Stay on CBI Proceedings and SBI Fraud Declaration Vivimed Labs has received an interim stay from the High Court of Telangana against all further proceedings from the Central Bureau of Investigation (CBI). The CBI had registered a case on 19 Nov'25 against the company and its directors for violations including the Prevention of Corruption Act. The court order, dated 06 Feb'26, also restrains State Bank of India from declaring the company's account as 'fraud'. The financial impact of these events cannot be quantified at this time.
Application filed for initiation of PPIRP
Others (Uncategorized) · 13 Feb 2026, 10:12 pm
Vivimed Labs Files for Pre-pack Insolvency Resolution Vivimed Labs submitted a Pre-pack Insolvency Resolution Process (PPIRP) application to the Insolvency and Bankruptcy Board of India (NCLT Bengaluru Bench) on 12th Feb'26. The application was filed under section 54A of the IBC Act. As of 31st Jan'26, the company reported an amount in default of ₹512.53 crore. This action follows previous intimations to the exchanges on 13th Nov'25 and 10th Jan'25 regarding its financial situation. The filing signals a significant step towards restructuring its debt under the IBC framework.
The Board Meeting to be held on 13/02/2026 Stands Cancelled.
Intimation · 11 Feb 2026, 6:20 pm
Vivimed Labs Postpones Board Meeting for Q3 FY26 Results Vivimed Labs Limited has postponed its Board Meeting originally scheduled for 13th Feb '26. The meeting was intended to approve the financial results for the third quarter of FY 2026. A new date will be communicated in due course. The trading window will remain closed for designated persons until 48 hours after the financial results are declared at the rescheduled meeting. This delay introduces uncertainty regarding the timing of the Q3 earnings release and subsequent market reaction.
updates
Others (Uncategorized) · 10 Feb 2026, 12:34 am
Vivimed Labs Obtains High Court Stay on CBI Search and Seizure Vivimed Labs has secured an interim stay from the Telangana High Court against all further proceedings related to a Search and Seizure conducted by the CBI on 20th Jan'26. The action was initiated based on a complaint from State Bank of India, which had declared Vivimed's account as 'fraud'. The court order restrains any coercive steps against the company and its directors on the basis of this search or the fraud notification, until further orders. The matter is scheduled for listing on 06th Mar'26.
Resignation of CFO
Change in Management · 06 Feb 2026, 5:31 pm
Vivimed Labs' CFO Phaninder Nath P S Resigns Citing Health Reasons Vivimed Labs Limited announced that Chief Financial Officer Mr. Phaninder Nath P S has resigned, citing personal health issues. His resignation is effective from the close of business hours on 06 Feb'26. Mr. Nath, who was also designated as Key Managerial Personnel and Senior Management Personnel, will cease all roles on this date. The company has initiated the necessary regulatory filings following the management change.
disclosure under regulation 30
Others (Uncategorized) · 03 Feb 2026, 10:17 pm
Vivimed Labs Executives Receive Notice from CBI Vivimed Labs' CFO and Company Secretary received a notice from the Central Bureau of Investigation (CBI) on 29 Jan'26. The notice relates to a complaint filed by State Bank of India regarding financial irregularities. The company also disclosed that its financial assets and associated dues owed to SBI have been acquired by Rare Asset Reconstruction Ltd. (Rare ARC) as per an assignment agreement from 25 Oct'25. Rare ARC is now entitled to recover the total dues from Vivimed Labs.
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 31st december 2025 results
Intimation · 13 Feb 2026, 5:30 am
Vivimed Labs Board Meeting Set for Feb 13, 2026 to Approve Q3 Results Vivimed Labs (NSE: VIVIMEDLAB) has scheduled a Board of Directors meeting for Friday, 13th Feb '26. The agenda includes the consideration and approval of the company's un-audited standalone and consolidated financial results for the quarter and nine months ending 31st Dec '25.
Re-lodgment of transfer requests for physical shares
Others (Uncategorized) · 13 Jan 2026, 11:02 pm
Vivimed Labs Reports No Physical Share Transfer Re-lodgement Requests As per the report from Registrar Aarthi Consultants dated 06 Jan '26, Vivimed Labs received zero requests for the re-lodgement of physical share transfers between 01 Dec '25 and 06 Jan '26. This intimation complies with the SEBI circular dated 02 Jul '25. The data indicates no activity in this specific category, with no requests received, processed, approved, or rejected during the specified period. This update, filed on 13 Jan '26, confirms a lack of physical share transfer re-lodgement activity from shareholders.
clarification on price movement
Others (Uncategorized) · 06 Jan 2026, 6:08 pm